Table 4– Repeat visits# in 22 haematopoietic stem cell transplantation recipients: changes in measured parameters
Parameters1st visit2nd visitp-values
Pulmonary function
 FEV1 % pred88±1585±210.27
 FVC % pred95±1594±180.76
 FEV1/FVC %78 (67–87)74 (47–85)0.08
 FEF25–75% % pred68±2662±290.09
 TLC % pred95±1097±100.12
 RV/TLC % pred99 (71–138)97 (73–165)0.62
DL,CO % pred72±1473±170.68
MBNW
 LCI11.6±2.513.5±3.50.003
 Scond L−10.06 (0.02–0.17)0.07 (0.02–0.24)0.21
 Sacin L−10.28 (0.06–0.69)0.41 (0.08–1.07)0.007
FOT % pred
Rrs113 (77–187)103 (73–259)0.50
Xrs151 (9–792)172 (47–788)0.37
eNO ppb7.5 (4.7–40.1)6.4 (3.6–16)0.46
SGRQ total score15 (0–40)17 (1–63)0.23
 Symptoms score21 (0–73)17 (0–68)0.93
 Activity score29±2533±270.45
 Impact score7 (0–22)6 (0–59)0.19
cGVHD grade0 (0–3)1 (0–3)0.38
  • Data are presented as mean±sd or median (range), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF25–75%: forced expiratory volume at 25–75% of FVC; TLC: total lung capacity; RV: residual volume; DL,CO: diffusing capacity of the lung for carbon monoxide; MBNW: multiple breath nitrogen washout; LCI: lung clearance index; Scond: index of conductive airways heterogeneity; Sacin: index of diffusive airways heterogeneity; FOT: forced oscillation technique; Rrs: respiratory system resistance; Xrs: respiratory system reactance; eNO: exhaled nitric oxide; SGRQ: St George’s Respiratory Questionnaire; cGVHD: chronic graft-versus-host disease. #: the second visits were performed 10±6 months after the first visits; : paired t-test or Wilcoxon signed rank test depending on the distribution of the differences.